Intravenous Ibandronate Acutely Reduces Bone Hyperresorption in Chronic Critical Illness

Abstract

Objective:

Patients who remain critically ill for prolonged periods and require tracheotomy, defined as chronic critical illness (CCI), display elevated levels of bone resorption. The measurement of bone turnover markers reveals that osteoclastic bone resorption is not only enhanced but also uncoupled from osteoblastic bone formation. We examine the effect of ibandronate on bone turnover in patients with CCI.

Methods:

This study is a prospective, double-blind, placebo-controlled trial, in which 20 postmenopausal female participants with CCI were followed for an 11-day period after the administration of a single intravenous dose of ibandronate (3 mg). All participants were treated with ergocalciferol (2000 IU daily), calcium carbonate (1250 mg daily), and calcitriol (0.25 μg daily).

Results:

The ibandronate group showed a 34% decrease in serum C-telopeptide (CTX) levels (a marker of osteoclastic activity) on day 6, while the placebo group showed a 13% increase (P = .01). By day 11, CTX levels in ibandronate group were not significantly different than baseline or from the placebo group. Osteocalcin (OCN) levels (a marker of osteoblast activity) increased by 78% compared to baseline in the ibandronate group (P = .01) and by 42% in the placebo group (P = .05). There were no significant differences in OCN between the 2 groups throughout the study. Parathyroid hormone levels remained constant throughout the study. No adverse events were observed.

Conclusion:

A single dose of intravenous ibandronate causes a significant but transient reduction in osteoclast activity in patients with CCI, which persists over a 6-day period.

Keywords

chronic critical illness ibandronate bone resorption osteoporosis

Get full access to this article

View all access options for this article.

References

Hollander

Mechanick

. Bisphosphonates and metabolic bone disease in the ICU. Curr Opin Clin Nutr Metab Care. 2009;12(2):190–195.

Hollander

Mechanick

. Nutrition support and the chronic critical illness syndrome. Nutr Clin Pract. 2006;21(6):587–604.

Nierman

Mechanick

. Bone hyperresorption is prevalent in chronically critically ill patients. Chest. 1998;114(4):1122–1128.

Smith

Cuthbertson

Harvie

Webster

Robins

Ralston

. Increased bone resorption in the critically ill: association with sepsis and increased nitric oxide production. Crit Care Med. 2002;30(4):837–840.

Van den Berghe

Van Roosbroeck

Vanhove

Wouters

De Pourcq

Bouillon

. Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab. 2003;88(10):4623–4632.

Boyce

Yao

. TNF-alpha and pathologic bone resorption. Keio J Med. 2005;54(3):127–131.

Lee

Eisman

Center

. Vitamin D deficiency in critically ill patients. N Engl J Med. 2009;360(18):1912–1914.

Price

Delisser

. Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis. J Bone Miner Res. 2005;20(1):117–124.

Chen

Mechanick

Nierman

Stein

. Combined calcitriol-pamidronate therapy for bone hyperresorption in spinal cord injury. J Spinal Cord Med. 2001;24(4):235–240.

10.

Van den Berghe

. Endocrine evaluation of patients with critical illness. Endocrinol Metab Clin North Am. 2003;32(2):385–410.

11.

Nussbaum

Younger

Vandepol

. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med. 1993;95(3):297–304.

12.

Nierman

Mechanick

. Biochemical response to treatment of bone hyperresorption in chronically critically ill patients. Chest. 2000;118(3):761–766.

13.

Bergner

Henrich

Hoffmann

. Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function. J Clin Pharmacol. 2007;47(8):942–950.

14.

Delmas

Adami

Strugala

. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006;54(6):1838–1846.

15.

Russell

Watts

Ebetino

Rogers

. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19(6):733–759.

16.

Dunford

Thompson

Coxon

. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296(2):235–242.

17.

Kavanagh

Guo

Dunford

. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A. 2006;103(20):7829–7834.

18.

Leu

Luegmayr

Freedman

Rodan

Reszka

. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone. 2006;38(5):628–636.

19.

Nancollas

Tang

Phipps

. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38(5):617–627.

20.

Rondeau

Bitsch

Bourgier

. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem. 2006;1(2):267–273.

21.

Pecherstorfer

Steinhauer

Rizzoli

Wetterwald

Bergstrom

. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer. 2003;11(8):539–547.

22.

Chen

Berenson

Vescio

. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42(11):1228–1236.

23.

Berenson

Rosen

Vescio

. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol. 1997;37(4):285–290.

24.

Papapetrou

. Bisphosphonate-associated adverse events. Hormones (Athens). 2009;8(2):96–110.

25.

Recker

Stakkestad

Chesnut

CH,

3rd . Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone. 2004;34(5):890–899.

26.

Garnero

Sornay-Rendu

Claustrat

Delmas

. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 2000;15(8):1526–1536.

27.

Van den Berghe

Baxter

Weekers

. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf). 2002;56(5):655–669.

28.

van den Berghe

Weekers

Baxter

. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness. J Clin Endocrinol Metab. 2001;86(7):3217–3226.

29.

Van den Berghe

Wouters

Weekers

. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab. 1999;84(4):1311–1323.